Angeliq Related Published Studies
Well-designed clinical trials related to Angeliq (Estradiol / Drospirenone)
Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women. [2011.08]
[Evaluation the efficacy and safety of estradiol and drospirenone tablets in the treatment of menopausal symptoms among postmenopausal Chinese healthy women:a randomized, multi-center, double-blind, placebo-controlled clinical study]. [2011.05]
Effects of estradiol-drospirenone hormone treatment on carotid artery intima-media thickness and vertigo/dizziness in postmenopausal women. [2011.05]
[Evaluation the efficacy and safety of estradiol and drospirenone tablets in the
treatment of menopausal symptoms among postmenopausal Chinese healthy women:a
randomized, multi-center, double-blind, placebo-controlled clinical study]. [Article in Chinese] [2011]
Angeliq versus Activelle in normotensive postmenopausal women: a prospective, randomized pilot study. [2009.07]
Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol + drospirenone and tibolone, on sexual function in healthy postmenopausal women. [2008.01]
Effect of estradiol-drospirenone hormone treatment on myocardial perfusion reserve in postmenopausal women with angina pectoris. [2007.06.15]
Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. [2006.02]
Well-designed clinical trials possibly related to Angeliq (Estradiol / Drospirenone)
Low-dose estrogen and drospirenone combination: effects on glycoinsulinemic metabolism and other cardiovascular risk factors in healthy postmenopausal women. [2011.01]
Other research related to Angeliq (Estradiol / Drospirenone)
Continuous-combined oral estradiol/drospirenone has no detrimental effect on
cognitive performance and improves estrogen deficiency symptoms in early
postmenopausal women: a randomized placebo-controlled trial. [2013]
Effects of estradiol-drospirenone on ocular and nasal functions in postmenopausal women. [2011.08]
Effects of estradiol-drospirenone hormone treatment on carotid artery
intima-media thickness and vertigo/dizziness in postmenopausal women. [2011]
Effects of estradiol-drospirenone hormone treatment on carotid artery intima-media thickness and vertigo/dizziness in postmenopausal women. [2010.05.05]
Angeliq versus Activelle in normotensive postmenopausal women: a prospective, randomized pilot study. [2009.02.03]
Characteristics of nasal epithelial cells in naturally postmenopausal women receiving hormone therapy with 1 mg 17beta-estradiol and 2 mg drospirenone: a prospective study. [2008.09]
The concomitant prescribing of ethinyl estradiol/drospirenone and potentially interacting drugs. [2007.10]
Coadministration of estradiol/drospirenone and indomethacin does not cause hyperkalemia in healthy postmenopausal women: a randomized open-label crossover study. [2007.06]
Coadministration of Estradiol/Drospirenone and Indomethacin Does Not Cause Hyperkalemia in Healthy Postmenopausal Women: A Randomized Open-Label Crossover Study. [2007.04.26]
Drospirenone with 17beta-estradiol in the postmenopausal woman with hypertension. [2007.02]
Drospirenone and estradiol: a new option for the postmenopausal woman. [2007.02]
Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes. [2007.02]
[Medication of the month. Angeliq: new hormonal therapy of menopause, with antialdosterone and antiandrogenic properties] [2004.03]
Other possibly related research studies
Effects of blood pressure reduction on cardiovascular risk estimates in hypertensive postmenopausal women. [2007.02]
Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism. [2006.11.20]
Added benefits of drospirenone for compliance. [2005.10]
Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. [2005.10]
Supplementary data collection with case-cohort analysis to address potential confounding in a cohort study of thromboembolism in oral contraceptive initiators matched on claims-based propensity scores. [2008.03]
[The impact of a new low dose oral contraceptive containing drospirenone on lipid profile, carbohydrate metabolism and hepatic function] [2009.02]
[The influence of a combined low dose oral contraceptive containing drospirenone on electrolite equlibrum and renal function in young woman] [2009.01]
[A young woman with cardiac arrest] [2010.01.14]
Low-dose estrogen and drospirenone combination: effects on glycoinsulinemic
metabolism and other cardiovascular risk factors in healthy postmenopausal women. [2011]
|